Lanadelumab in Long-term Prophylaxis of Acquired Angioedema

Recruiting now · Phase 4

Conditions studied: Angioedema

In brief

use of lanadelumab in patients with acquired angioedema

Key facts

Study ID

NCT06818474

Run by

Bernstein Clinical Research Center

People needed

5

Starts

2024-06-01

Expected to finish

2027-12-01

Last updated by the study team

2025-02-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A diagnosis of AAE with recurrent attacks without urticaria (decreased C1INH functional, quantitative levels, decreased C4 and decreased C1q levels, no family history of angioedema), presence of anti-C1INH antibody and/or paraproteinemia (e.g. monoclonal gammopathy of unknown significance)
• historical attack rate of >= on attack per month prior to starting tranexamic acid (TAA)

You may not qualify if…

• History of anaphylaxis or hypersensitivity to biologics
• History of major systemic disease not well controlled in opinion of the PI
• Women who are pregnant or breast feeding
• Concurrent participation in other clinical trials
• HAE Type 1 or 2 and normal complement HAE

Where it is running

• Bernstein Clinical Research Center, LLC — Cincinnati, Ohio, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.